Skip to main content

Table 2 Weighted cost savings and budget impact per DRG and scenario [in €]

From: A budget impact analysis of bezlotoxumab versus standard of care antibiotics only in patients at high risk of CDI recurrence from a hospital management perspective in Germany

 

No case consolidation (A)

Case consolidation for SoC + bezlotoxumab (B)

Case consolidation for both treatment arms (C)

DRG

Weighted cost savings

Budget

Impact

Weighted cost savings

Budget Impact

Weighted cost savings

Budget Impact

SoC

SoC + bezlo

SoC

SoC + bezlo

SoC

SoC + bezlo

B44C

744.47

1,174.21

-429.73

744.47

1,132.45

-387.97

582.64

1,132.45

-549.81

G67A

324.13

935.95

-611.83

324.13

917.38

-593.26

252.17

917.38

-665.21

G48A

697.72

1,339.91

-642.19

697.72

1,299.49

-601.77

541.07

1,299.49

-758.41

G52Z

860.39

1,289.17

-428.78

860.39

1,241.03

-380.64

673.82

1,241.03

-567.21

G77A

908.73

1,423.06

-514.33

908.73

1,370.81

-462.08

706.21

1,370.81

-664.59

G77B

518.28

1,014.29

-496.02

518.28

984.81

-466.54

404.04

984.81

-580.78

E42Z

853.25

1,282.24

-428.99

853.25

1,234.54

-381.30

668.41

1,234.54

-566.13

E79A

555.65

1,111.34

-555.69

555.65

1,079.79

-524.14

433.37

1,079.79

-646.42

T60€

431.28

984.46

-553.18

431.28

959.83

-528.55

335.83

959.83

-624.00

F48Z

828.86

1,253.70

-424.85

828.86

1,207.61

-378.75

650.20

1,207.61

-557.40

Average

672.27

1,180.83

-508.56

672.27

1,142.77

-470.50

524.78

1,142.77

-618.00

  1. Note: Weighted cost savings = Sum of cost savings for each possible treatment outcome multiplied by the probability of occurrence (Fig. 1)